| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 124 | 2018 | 16215 | 4.220 |
Why?
|
| Tumor Suppressor Protein p53 | 29 | 2014 | 3658 | 1.550 |
Why?
|
| Tamoxifen | 16 | 2013 | 875 | 1.360 |
Why?
|
| Metformin | 6 | 2014 | 393 | 1.290 |
Why?
|
| Breast | 10 | 2011 | 1369 | 1.260 |
Why?
|
| Medical Audit | 15 | 2014 | 195 | 1.220 |
Why?
|
| Receptors, Estrogen | 13 | 2014 | 2170 | 1.180 |
Why?
|
| Receptor, ErbB-2 | 12 | 2014 | 2651 | 1.180 |
Why?
|
| Scotland | 20 | 2013 | 43 | 1.170 |
Why?
|
| Carcinoma in Situ | 7 | 2018 | 489 | 1.160 |
Why?
|
| Surgical Procedures, Operative | 6 | 2011 | 359 | 1.120 |
Why?
|
| Carcinoma, Ductal, Breast | 8 | 2018 | 1229 | 1.070 |
Why?
|
| Receptors, Progesterone | 7 | 2014 | 1604 | 1.050 |
Why?
|
| Biomarkers, Tumor | 20 | 2014 | 10708 | 1.010 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2013 | 275 | 0.960 |
Why?
|
| Genes, p53 | 15 | 2013 | 1140 | 0.930 |
Why?
|
| Neoplasms, Hormone-Dependent | 5 | 2012 | 347 | 0.910 |
Why?
|
| Elasticity Imaging Techniques | 5 | 2013 | 186 | 0.900 |
Why?
|
| Antineoplastic Agents, Hormonal | 11 | 2018 | 841 | 0.880 |
Why?
|
| Female | 145 | 2018 | 148940 | 0.820 |
Why?
|
| Esophageal Neoplasms | 10 | 2012 | 3240 | 0.800 |
Why?
|
| Mastectomy | 8 | 2018 | 1553 | 0.750 |
Why?
|
| Ultrasonography, Mammary | 3 | 2012 | 387 | 0.720 |
Why?
|
| Humans | 188 | 2018 | 270740 | 0.700 |
Why?
|
| Aromatase Inhibitors | 6 | 2013 | 311 | 0.650 |
Why?
|
| Hypoglycemic Agents | 4 | 2014 | 599 | 0.640 |
Why?
|
| Cholecystectomy | 2 | 2011 | 118 | 0.620 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2014 | 402 | 0.610 |
Why?
|
| Tissue Array Analysis | 4 | 2013 | 757 | 0.600 |
Why?
|
| United Kingdom | 9 | 2018 | 287 | 0.590 |
Why?
|
| Surgery Department, Hospital | 3 | 2012 | 27 | 0.580 |
Why?
|
| Medication Adherence | 6 | 2013 | 513 | 0.570 |
Why?
|
| Mastectomy, Segmental | 6 | 2018 | 1049 | 0.550 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2018 | 10400 | 0.540 |
Why?
|
| Breast Diseases | 3 | 2012 | 200 | 0.540 |
Why?
|
| Dactinomycin | 2 | 2013 | 163 | 0.540 |
Why?
|
| Hospital Mortality | 5 | 2012 | 1234 | 0.530 |
Why?
|
| Aged, 80 and over | 38 | 2018 | 30998 | 0.510 |
Why?
|
| Esophagectomy | 4 | 2012 | 946 | 0.510 |
Why?
|
| Lymph Nodes | 6 | 2013 | 3077 | 0.490 |
Why?
|
| Chromosomes, Human, Pair 17 | 9 | 2002 | 668 | 0.490 |
Why?
|
| Aged | 57 | 2018 | 73333 | 0.490 |
Why?
|
| Cytochrome P-450 CYP2D6 | 3 | 2013 | 45 | 0.490 |
Why?
|
| Research | 3 | 2013 | 427 | 0.470 |
Why?
|
| Sentinel Lymph Node Biopsy | 5 | 2012 | 1458 | 0.470 |
Why?
|
| Middle Aged | 63 | 2018 | 90352 | 0.460 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 8 | 2014 | 525 | 0.460 |
Why?
|
| Muscle Proteins | 2 | 2012 | 551 | 0.460 |
Why?
|
| Biopsy | 7 | 2013 | 3484 | 0.440 |
Why?
|
| Radiation Tolerance | 2 | 2010 | 639 | 0.430 |
Why?
|
| Estrogen Receptor Modulators | 2 | 2010 | 110 | 0.430 |
Why?
|
| Adult | 52 | 2014 | 82040 | 0.420 |
Why?
|
| Carcinoma | 8 | 2013 | 2610 | 0.420 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2012 | 56 | 0.420 |
Why?
|
| Hexokinase | 1 | 2012 | 36 | 0.420 |
Why?
|
| Pattern Recognition, Automated | 1 | 2013 | 120 | 0.410 |
Why?
|
| Postoperative Complications | 7 | 2013 | 5681 | 0.410 |
Why?
|
| DNA, Neoplasm | 7 | 2013 | 1958 | 0.410 |
Why?
|
| Temperament | 1 | 2012 | 28 | 0.410 |
Why?
|
| Antineoplastic Agents | 13 | 2014 | 14617 | 0.410 |
Why?
|
| Cell Line, Tumor | 29 | 2014 | 14849 | 0.410 |
Why?
|
| Phenformin | 1 | 2012 | 5 | 0.410 |
Why?
|
| Prospective Studies | 19 | 2018 | 13414 | 0.410 |
Why?
|
| Survival Analysis | 17 | 2018 | 9292 | 0.410 |
Why?
|
| Tissue Banks | 1 | 2012 | 51 | 0.400 |
Why?
|
| Gene Expression Regulation, Neoplastic | 21 | 2014 | 9042 | 0.400 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 341 | 0.400 |
Why?
|
| Prealbumin | 1 | 2012 | 38 | 0.400 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2012 | 44 | 0.400 |
Why?
|
| Serum Amyloid A Protein | 1 | 2012 | 40 | 0.400 |
Why?
|
| Apolipoprotein A-I | 1 | 2012 | 95 | 0.400 |
Why?
|
| Microscopy | 1 | 2013 | 189 | 0.400 |
Why?
|
| Prognosis | 26 | 2013 | 22505 | 0.390 |
Why?
|
| Stomach Neoplasms | 8 | 2007 | 2331 | 0.390 |
Why?
|
| Mass Screening | 2 | 2018 | 1552 | 0.380 |
Why?
|
| Signal Transduction | 11 | 2012 | 12103 | 0.380 |
Why?
|
| Axilla | 6 | 2013 | 939 | 0.380 |
Why?
|
| Cancer Care Facilities | 2 | 2013 | 907 | 0.380 |
Why?
|
| Models, Biological | 9 | 2014 | 3194 | 0.370 |
Why?
|
| Introns | 2 | 2011 | 461 | 0.370 |
Why?
|
| Gallstones | 1 | 2011 | 64 | 0.370 |
Why?
|
| Treatment Outcome | 21 | 2018 | 33737 | 0.370 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 2011 | 75 | 0.370 |
Why?
|
| RNA, Messenger | 18 | 2012 | 6390 | 0.360 |
Why?
|
| Blood Proteins | 1 | 2012 | 299 | 0.360 |
Why?
|
| Psychosocial Deprivation | 1 | 2010 | 8 | 0.350 |
Why?
|
| Referral and Consultation | 2 | 2013 | 931 | 0.350 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 606 | 0.350 |
Why?
|
| Pain, Postoperative | 2 | 2013 | 662 | 0.340 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 306 | 0.340 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 368 | 0.340 |
Why?
|
| Emergencies | 2 | 2011 | 224 | 0.340 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2012 | 550 | 0.330 |
Why?
|
| Early Detection of Cancer | 3 | 2014 | 1340 | 0.330 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2012 | 625 | 0.330 |
Why?
|
| Mortality | 3 | 2005 | 347 | 0.320 |
Why?
|
| Doxorubicin | 2 | 2009 | 3145 | 0.320 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2012 | 1260 | 0.320 |
Why?
|
| Gamma Rays | 1 | 2009 | 237 | 0.310 |
Why?
|
| Chronic Pain | 1 | 2012 | 262 | 0.310 |
Why?
|
| Gene Amplification | 2 | 2010 | 766 | 0.310 |
Why?
|
| Epithelium | 1 | 2010 | 782 | 0.310 |
Why?
|
| Peer Review | 2 | 2005 | 82 | 0.310 |
Why?
|
| Neoplasm Invasiveness | 7 | 2012 | 4048 | 0.310 |
Why?
|
| Stromal Cells | 1 | 2012 | 825 | 0.310 |
Why?
|
| Imidazoles | 2 | 2013 | 1065 | 0.310 |
Why?
|
| Cyclin D1 | 1 | 2010 | 589 | 0.300 |
Why?
|
| Models, Animal | 1 | 2010 | 657 | 0.300 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2013 | 2453 | 0.300 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2013 | 2271 | 0.300 |
Why?
|
| Chromosome Deletion | 6 | 2001 | 1049 | 0.300 |
Why?
|
| Piperazines | 3 | 2013 | 2145 | 0.300 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 6 | 2014 | 690 | 0.300 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2013 | 1302 | 0.290 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 787 | 0.290 |
Why?
|
| Esophagogastric Junction | 3 | 2011 | 557 | 0.290 |
Why?
|
| Terminal Care | 1 | 2012 | 467 | 0.290 |
Why?
|
| Purines | 1 | 2009 | 271 | 0.290 |
Why?
|
| Linkage Disequilibrium | 1 | 2008 | 494 | 0.290 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2009 | 319 | 0.290 |
Why?
|
| Cholecystitis | 1 | 2007 | 59 | 0.280 |
Why?
|
| Flow Cytometry | 2 | 2013 | 3045 | 0.280 |
Why?
|
| Cyclins | 2 | 2006 | 467 | 0.280 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2009 | 236 | 0.280 |
Why?
|
| Sensitivity and Specificity | 8 | 2013 | 5162 | 0.270 |
Why?
|
| Neoplasm, Residual | 2 | 2013 | 1754 | 0.270 |
Why?
|
| Proteomics | 2 | 2012 | 1427 | 0.270 |
Why?
|
| Immunohistochemistry | 11 | 2012 | 7655 | 0.270 |
Why?
|
| Animals | 29 | 2014 | 61956 | 0.270 |
Why?
|
| Medical Oncology | 2 | 2011 | 1465 | 0.260 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 2650 | 0.260 |
Why?
|
| Reproducibility of Results | 9 | 2013 | 6177 | 0.260 |
Why?
|
| Biopsy, Needle | 6 | 2012 | 1379 | 0.250 |
Why?
|
| Neoplasm Proteins | 5 | 2008 | 3345 | 0.250 |
Why?
|
| Social Responsibility | 1 | 2005 | 92 | 0.250 |
Why?
|
| Transforming Growth Factor beta | 5 | 2010 | 1109 | 0.250 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 1330 | 0.250 |
Why?
|
| False Negative Reactions | 1 | 2005 | 291 | 0.250 |
Why?
|
| Intraoperative Complications | 1 | 2007 | 288 | 0.240 |
Why?
|
| Mammaplasty | 3 | 2009 | 714 | 0.240 |
Why?
|
| Anesthesia | 2 | 2005 | 301 | 0.240 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2010 | 2313 | 0.240 |
Why?
|
| Biomedical Research | 2 | 2010 | 801 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 4 | 2013 | 5231 | 0.240 |
Why?
|
| Nurse's Role | 1 | 2004 | 45 | 0.230 |
Why?
|
| Family Practice | 2 | 2012 | 131 | 0.230 |
Why?
|
| Quality Assurance, Health Care | 3 | 2005 | 596 | 0.230 |
Why?
|
| Neovascularization, Pathologic | 2 | 2008 | 1586 | 0.230 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2018 | 4000 | 0.230 |
Why?
|
| Retinoids | 1 | 2004 | 149 | 0.230 |
Why?
|
| Microarray Analysis | 1 | 2005 | 396 | 0.230 |
Why?
|
| Neoplasms, Experimental | 1 | 2007 | 784 | 0.230 |
Why?
|
| Lymph Node Excision | 2 | 2004 | 2062 | 0.230 |
Why?
|
| Lymphatic Metastasis | 10 | 2013 | 4963 | 0.220 |
Why?
|
| Protein Kinases | 1 | 2008 | 902 | 0.220 |
Why?
|
| Mice, Nude | 7 | 2012 | 4329 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2013 | 16689 | 0.220 |
Why?
|
| Estrogen Receptor alpha | 1 | 2008 | 692 | 0.220 |
Why?
|
| Chromosome Aberrations | 4 | 2002 | 2035 | 0.220 |
Why?
|
| Mutation | 13 | 2013 | 15912 | 0.220 |
Why?
|
| Enzyme Activation | 4 | 2012 | 1810 | 0.220 |
Why?
|
| Palliative Care | 3 | 2013 | 2178 | 0.220 |
Why?
|
| Alleles | 8 | 1998 | 2600 | 0.220 |
Why?
|
| Surgical Flaps | 1 | 2009 | 894 | 0.220 |
Why?
|
| Estrogens | 5 | 2008 | 805 | 0.220 |
Why?
|
| Mice, SCID | 3 | 2012 | 1826 | 0.210 |
Why?
|
| Esophagoscopy | 1 | 2004 | 310 | 0.210 |
Why?
|
| Phosphorylation | 8 | 2013 | 4942 | 0.200 |
Why?
|
| Transplantation, Heterologous | 5 | 2012 | 1054 | 0.200 |
Why?
|
| Neoplasms | 10 | 2013 | 15927 | 0.200 |
Why?
|
| Mice | 18 | 2012 | 35600 | 0.200 |
Why?
|
| Cohort Studies | 14 | 2014 | 9470 | 0.200 |
Why?
|
| Endoscopy, Digestive System | 1 | 2003 | 210 | 0.200 |
Why?
|
| DNA Methylation | 7 | 2013 | 2765 | 0.200 |
Why?
|
| Vinblastine | 1 | 2003 | 462 | 0.200 |
Why?
|
| 5'-Nucleotidase | 2 | 2012 | 63 | 0.200 |
Why?
|
| Neoplasm Metastasis | 8 | 2013 | 5315 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2014 | 5408 | 0.190 |
Why?
|
| Drug Resistance, Multiple | 1 | 2002 | 221 | 0.190 |
Why?
|
| Ki-67 Antigen | 3 | 2013 | 675 | 0.190 |
Why?
|
| Preoperative Period | 2 | 2012 | 346 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2002 | 257 | 0.190 |
Why?
|
| CpG Islands | 6 | 2013 | 671 | 0.190 |
Why?
|
| G2 Phase | 1 | 2001 | 218 | 0.190 |
Why?
|
| Cost of Illness | 1 | 2004 | 505 | 0.190 |
Why?
|
| Procollagen-Proline Dioxygenase | 2 | 2012 | 44 | 0.190 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 3409 | 0.190 |
Why?
|
| Guideline Adherence | 3 | 2013 | 632 | 0.190 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 2 | 2010 | 6 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2014 | 3917 | 0.180 |
Why?
|
| Chromosomes, Human | 1 | 2001 | 288 | 0.180 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 4328 | 0.180 |
Why?
|
| Hernia | 1 | 2000 | 45 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 669 | 0.180 |
Why?
|
| Combined Modality Therapy | 6 | 2018 | 9039 | 0.180 |
Why?
|
| Apoptosis | 7 | 2013 | 7757 | 0.170 |
Why?
|
| Adenocarcinoma | 9 | 2013 | 7914 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2012 | 2617 | 0.170 |
Why?
|
| Disease-Free Survival | 7 | 2013 | 10265 | 0.170 |
Why?
|
| Laser Therapy | 1 | 2004 | 466 | 0.170 |
Why?
|
| Patient Discharge | 1 | 2004 | 698 | 0.160 |
Why?
|
| Clinical Trials as Topic | 4 | 2014 | 3844 | 0.160 |
Why?
|
| Follow-Up Studies | 12 | 2013 | 15218 | 0.160 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 3 | 2013 | 173 | 0.160 |
Why?
|
| Patient Satisfaction | 1 | 2004 | 917 | 0.160 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2011 | 256 | 0.160 |
Why?
|
| Regression Analysis | 4 | 2011 | 1571 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2010 | 537 | 0.160 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 7381 | 0.160 |
Why?
|
| Pain Measurement | 2 | 2013 | 1016 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2014 | 5776 | 0.160 |
Why?
|
| Colorectal Neoplasms | 2 | 2013 | 3707 | 0.150 |
Why?
|
| Herniorrhaphy | 1 | 2000 | 179 | 0.150 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 4831 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 4481 | 0.150 |
Why?
|
| RNA, Neoplasm | 7 | 2008 | 805 | 0.150 |
Why?
|
| Male | 25 | 2013 | 128315 | 0.150 |
Why?
|
| Homeodomain Proteins | 3 | 2012 | 1125 | 0.150 |
Why?
|
| Enzyme Inhibitors | 4 | 2012 | 1942 | 0.150 |
Why?
|
| Benzofurans | 2 | 2010 | 40 | 0.150 |
Why?
|
| Stents | 1 | 2004 | 999 | 0.150 |
Why?
|
| Gene Expression | 6 | 2010 | 3640 | 0.150 |
Why?
|
| Minor Surgical Procedures | 1 | 1997 | 3 | 0.150 |
Why?
|
| Groin | 1 | 1997 | 78 | 0.140 |
Why?
|
| Proteins | 2 | 1998 | 2043 | 0.140 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2006 | 375 | 0.140 |
Why?
|
| Gene Frequency | 2 | 2010 | 1246 | 0.140 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 5002 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 7895 | 0.140 |
Why?
|
| Athletic Injuries | 1 | 1997 | 70 | 0.140 |
Why?
|
| Nucleic Acid Hybridization | 5 | 2004 | 632 | 0.140 |
Why?
|
| Predictive Value of Tests | 4 | 2013 | 4960 | 0.140 |
Why?
|
| Gene Silencing | 6 | 2012 | 827 | 0.140 |
Why?
|
| Retrospective Studies | 12 | 2013 | 39890 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 4644 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2001 | 1275 | 0.140 |
Why?
|
| Risk Assessment | 6 | 2013 | 6764 | 0.130 |
Why?
|
| Cell Cycle | 4 | 2012 | 2137 | 0.130 |
Why?
|
| Databases, Factual | 3 | 2012 | 2250 | 0.130 |
Why?
|
| Drug Interactions | 2 | 2010 | 572 | 0.130 |
Why?
|
| Cognition | 2 | 2012 | 959 | 0.130 |
Why?
|
| Time Factors | 7 | 2011 | 13006 | 0.130 |
Why?
|
| Menopause | 3 | 2013 | 160 | 0.120 |
Why?
|
| Azacitidine | 1 | 2001 | 1218 | 0.120 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2007 | 232 | 0.120 |
Why?
|
| Ultraviolet Rays | 2 | 2012 | 588 | 0.120 |
Why?
|
| Epigenesis, Genetic | 3 | 2012 | 1441 | 0.120 |
Why?
|
| Neoplasm Transplantation | 4 | 2012 | 1553 | 0.120 |
Why?
|
| Serine | 2 | 2010 | 391 | 0.120 |
Why?
|
| Bandages | 2 | 2002 | 75 | 0.120 |
Why?
|
| Incidence | 4 | 2012 | 5824 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2014 | 1563 | 0.120 |
Why?
|
| Gene Expression Profiling | 5 | 2011 | 5149 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2001 | 189 | 0.120 |
Why?
|
| Protein Isoforms | 4 | 2011 | 848 | 0.110 |
Why?
|
| Histones | 2 | 2012 | 1513 | 0.110 |
Why?
|
| Neoplasm Grading | 3 | 2014 | 1823 | 0.110 |
Why?
|
| Phenotype | 6 | 2014 | 6509 | 0.110 |
Why?
|
| Protein Biosynthesis | 3 | 2013 | 1028 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2001 | 275 | 0.110 |
Why?
|
| Genotype | 3 | 2013 | 4252 | 0.110 |
Why?
|
| Genes, APC | 1 | 1993 | 71 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 5 | 2012 | 1126 | 0.110 |
Why?
|
| Proportional Hazards Models | 5 | 2014 | 5101 | 0.110 |
Why?
|
| RNA, Ribosomal | 1 | 2013 | 94 | 0.110 |
Why?
|
| Surgical Instruments | 1 | 2013 | 141 | 0.110 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 336 | 0.110 |
Why?
|
| Laparotomy | 2 | 2011 | 235 | 0.110 |
Why?
|
| Accidents, Aviation | 1 | 1992 | 7 | 0.110 |
Why?
|
| Breast Neoplasms, Male | 2 | 2013 | 232 | 0.100 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 2115 | 0.100 |
Why?
|
| Aircraft | 1 | 1992 | 28 | 0.100 |
Why?
|
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2012 | 15 | 0.100 |
Why?
|
| Spironolactone | 1 | 2012 | 23 | 0.100 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 1993 | 103 | 0.100 |
Why?
|
| Radiotherapy | 2 | 2018 | 1857 | 0.100 |
Why?
|
| Ireland | 1 | 2012 | 31 | 0.100 |
Why?
|
| Respiration Disorders | 1 | 1992 | 48 | 0.100 |
Why?
|
| Postmenopause | 2 | 2012 | 375 | 0.100 |
Why?
|
| Sterilization | 1 | 2002 | 13 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 497 | 0.100 |
Why?
|
| Microtubules | 2 | 2012 | 329 | 0.100 |
Why?
|
| Intraoperative Care | 1 | 2013 | 274 | 0.100 |
Why?
|
| Adenylate Kinase | 1 | 2012 | 36 | 0.100 |
Why?
|
| Nuclear Envelope | 1 | 2012 | 39 | 0.100 |
Why?
|
| Estrogen Receptor beta | 1 | 2012 | 149 | 0.100 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2011 | 10 | 0.100 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 353 | 0.100 |
Why?
|
| General Practice | 1 | 2011 | 8 | 0.100 |
Why?
|
| Diuretics | 1 | 2012 | 170 | 0.100 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 206 | 0.100 |
Why?
|
| Aspirin | 1 | 2014 | 375 | 0.100 |
Why?
|
| Genes, BRCA2 | 2 | 2008 | 322 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2010 | 561 | 0.090 |
Why?
|
| Estrogen Antagonists | 1 | 2012 | 188 | 0.090 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2012 | 162 | 0.090 |
Why?
|
| Nipples | 1 | 1991 | 122 | 0.090 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2011 | 71 | 0.090 |
Why?
|
| Fistula | 1 | 1991 | 77 | 0.090 |
Why?
|
| Genes, BRCA1 | 2 | 2008 | 397 | 0.090 |
Why?
|
| Fibroadenoma | 1 | 2010 | 27 | 0.090 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2013 | 376 | 0.090 |
Why?
|
| Western Australia | 2 | 2012 | 6 | 0.090 |
Why?
|
| Needs Assessment | 1 | 2012 | 238 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2014 | 486 | 0.090 |
Why?
|
| Logistic Models | 3 | 2012 | 3444 | 0.090 |
Why?
|
| Intracellular Space | 1 | 2010 | 78 | 0.090 |
Why?
|
| Adolescent | 5 | 2013 | 32767 | 0.090 |
Why?
|
| Health Priorities | 1 | 2010 | 46 | 0.090 |
Why?
|
| Gastrectomy | 3 | 2005 | 476 | 0.090 |
Why?
|
| Pancreatectomy | 2 | 2013 | 696 | 0.090 |
Why?
|
| Standard of Care | 1 | 2012 | 277 | 0.090 |
Why?
|
| Specimen Handling | 1 | 2012 | 307 | 0.090 |
Why?
|
| Triazoles | 2 | 2012 | 627 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 540 | 0.090 |
Why?
|
| Antimitotic Agents | 1 | 2010 | 8 | 0.090 |
Why?
|
| Mutant Proteins | 1 | 2011 | 234 | 0.090 |
Why?
|
| Keratinocytes | 2 | 2011 | 244 | 0.090 |
Why?
|
| Acute Disease | 2 | 2007 | 2493 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2012 | 322 | 0.090 |
Why?
|
| Mammography | 4 | 2013 | 1052 | 0.090 |
Why?
|
| Epirubicin | 1 | 2010 | 159 | 0.090 |
Why?
|
| Oncogenes | 4 | 2007 | 699 | 0.090 |
Why?
|
| Nitriles | 2 | 2012 | 939 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 558 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2013 | 647 | 0.090 |
Why?
|
| Safety Management | 1 | 2011 | 135 | 0.090 |
Why?
|
| Genome | 1 | 2013 | 690 | 0.090 |
Why?
|
| Trastuzumab | 1 | 2012 | 743 | 0.090 |
Why?
|
| Transcription, Genetic | 4 | 2012 | 3339 | 0.090 |
Why?
|
| Risk Factors | 7 | 2013 | 17888 | 0.080 |
Why?
|
| Phosphoserine | 2 | 1999 | 109 | 0.080 |
Why?
|
| Melanoma | 3 | 2013 | 5595 | 0.080 |
Why?
|
| Loss of Heterozygosity | 3 | 2001 | 623 | 0.080 |
Why?
|
| Spleen | 1 | 2012 | 726 | 0.080 |
Why?
|
| Tissue Expansion | 1 | 1990 | 71 | 0.080 |
Why?
|
| Conserved Sequence | 1 | 2011 | 498 | 0.080 |
Why?
|
| Caspase 3 | 1 | 2010 | 474 | 0.080 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 704 | 0.080 |
Why?
|
| Collagen | 1 | 2012 | 727 | 0.080 |
Why?
|
| Research Design | 2 | 2012 | 1569 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2012 | 5438 | 0.080 |
Why?
|
| Age Factors | 4 | 2013 | 5457 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 6 | 2011 | 5759 | 0.080 |
Why?
|
| Friends | 1 | 2009 | 23 | 0.080 |
Why?
|
| Chromosome Disorders | 2 | 2001 | 423 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2013 | 779 | 0.080 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 751 | 0.080 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2010 | 199 | 0.080 |
Why?
|
| Linear Models | 1 | 2012 | 1093 | 0.080 |
Why?
|
| Tubulin Modulators | 1 | 2008 | 65 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2014 | 1192 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 354 | 0.080 |
Why?
|
| Recurrence | 3 | 2012 | 4878 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 984 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2013 | 425 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 628 | 0.080 |
Why?
|
| Disease Progression | 3 | 2012 | 6867 | 0.080 |
Why?
|
| Nuclear Proteins | 5 | 2011 | 3438 | 0.080 |
Why?
|
| Evaluation Studies as Topic | 4 | 2013 | 452 | 0.080 |
Why?
|
| Social Class | 1 | 2010 | 324 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1189 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2010 | 329 | 0.080 |
Why?
|
| Laparoscopy | 1 | 1997 | 1302 | 0.080 |
Why?
|
| Comorbidity | 2 | 2013 | 2394 | 0.080 |
Why?
|
| Blotting, Northern | 2 | 2004 | 726 | 0.070 |
Why?
|
| Organ Size | 1 | 2009 | 692 | 0.070 |
Why?
|
| Oncogene Proteins | 1 | 1990 | 367 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 299 | 0.070 |
Why?
|
| Carcinoma, Lobular | 2 | 2010 | 616 | 0.070 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2008 | 128 | 0.070 |
Why?
|
| Alternative Splicing | 1 | 2011 | 611 | 0.070 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 503 | 0.070 |
Why?
|
| Embolism, Air | 1 | 1987 | 35 | 0.070 |
Why?
|
| ErbB Receptors | 2 | 2012 | 2375 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 3597 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 1312 | 0.070 |
Why?
|
| Thermography | 1 | 2007 | 57 | 0.070 |
Why?
|
| Genomic Instability | 1 | 2010 | 521 | 0.070 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 387 | 0.070 |
Why?
|
| Reoperation | 1 | 2012 | 1392 | 0.070 |
Why?
|
| Evidence-Based Medicine | 2 | 2012 | 1034 | 0.070 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 1002 | 0.070 |
Why?
|
| Disease Management | 1 | 2012 | 1090 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 904 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2011 | 6256 | 0.070 |
Why?
|
| Quality of Life | 4 | 2013 | 4761 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2014 | 7238 | 0.070 |
Why?
|
| Evolution, Molecular | 1 | 2011 | 867 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2011 | 551 | 0.070 |
Why?
|
| Cyclin D | 1 | 2006 | 39 | 0.070 |
Why?
|
| Cisplatin | 2 | 2012 | 2497 | 0.070 |
Why?
|
| Heart Diseases | 1 | 1992 | 724 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2012 | 1567 | 0.070 |
Why?
|
| Age of Onset | 1 | 2008 | 853 | 0.070 |
Why?
|
| DNA Replication | 1 | 2010 | 770 | 0.070 |
Why?
|
| Trefoil Factor-1 | 2 | 1998 | 16 | 0.070 |
Why?
|
| Blotting, Western | 4 | 2007 | 3584 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2012 | 2033 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 1456 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2010 | 1990 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2009 | 728 | 0.060 |
Why?
|
| Vincristine | 1 | 2010 | 1583 | 0.060 |
Why?
|
| Social Support | 2 | 2009 | 590 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2010 | 1418 | 0.060 |
Why?
|
| Professional Practice | 1 | 2005 | 80 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 1 | 2012 | 929 | 0.060 |
Why?
|
| Insulin | 1 | 2011 | 1483 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2009 | 1356 | 0.060 |
Why?
|
| Skin Neoplasms | 2 | 2013 | 4895 | 0.060 |
Why?
|
| Australia | 1 | 2005 | 259 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 1993 | 1435 | 0.060 |
Why?
|
| Young Adult | 3 | 2013 | 22251 | 0.060 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2014 | 1386 | 0.060 |
Why?
|
| Myelopoiesis | 1 | 2005 | 34 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2011 | 5593 | 0.060 |
Why?
|
| Mammary Glands, Human | 1 | 2006 | 182 | 0.060 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2004 | 94 | 0.060 |
Why?
|
| Receptors, sigma | 1 | 2004 | 6 | 0.060 |
Why?
|
| Emergency Treatment | 1 | 2005 | 104 | 0.060 |
Why?
|
| Family | 1 | 2009 | 783 | 0.060 |
Why?
|
| Neoplasm Staging | 4 | 2013 | 14012 | 0.060 |
Why?
|
| Hemorheology | 1 | 2004 | 39 | 0.060 |
Why?
|
| Trust | 1 | 2005 | 109 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2010 | 2069 | 0.060 |
Why?
|
| Age Distribution | 2 | 2011 | 727 | 0.060 |
Why?
|
| Catheterization, Central Venous | 1 | 1987 | 363 | 0.060 |
Why?
|
| Accreditation | 1 | 2005 | 137 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 1990 | 1138 | 0.060 |
Why?
|
| Decision Making | 1 | 2012 | 1252 | 0.060 |
Why?
|
| Genistein | 1 | 2004 | 74 | 0.060 |
Why?
|
| Pulsatile Flow | 1 | 2004 | 142 | 0.060 |
Why?
|
| Isoflavones | 1 | 2004 | 74 | 0.060 |
Why?
|
| Hospitals, Teaching | 1 | 2004 | 125 | 0.060 |
Why?
|
| Chromosome Mapping | 5 | 2001 | 1655 | 0.060 |
Why?
|
| Health Services | 1 | 2004 | 100 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2007 | 636 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 1024 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2005 | 1325 | 0.050 |
Why?
|
| Epithelial Cells | 1 | 2010 | 1875 | 0.050 |
Why?
|
| Retinoblastoma Protein | 1 | 2005 | 339 | 0.050 |
Why?
|
| Models, Cardiovascular | 1 | 2004 | 189 | 0.050 |
Why?
|
| Registries | 3 | 2013 | 2211 | 0.050 |
Why?
|
| Survival Rate | 3 | 2012 | 12541 | 0.050 |
Why?
|
| DNA Probes | 3 | 1993 | 247 | 0.050 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2004 | 367 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2004 | 322 | 0.050 |
Why?
|
| Base Sequence | 5 | 2011 | 5437 | 0.050 |
Why?
|
| Down-Regulation | 4 | 2012 | 2090 | 0.050 |
Why?
|
| Hospitalization | 1 | 2012 | 2167 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2013 | 6224 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2004 | 180 | 0.050 |
Why?
|
| Intestinal Perforation | 1 | 2003 | 108 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2011 | 2098 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 689 | 0.050 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2003 | 131 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2010 | 2101 | 0.050 |
Why?
|
| Gloves, Surgical | 1 | 1992 | 11 | 0.050 |
Why?
|
| Cardia | 2 | 1999 | 45 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2004 | 200 | 0.050 |
Why?
|
| DNA Repair | 1 | 2010 | 1909 | 0.050 |
Why?
|
| Materials Testing | 1 | 1992 | 119 | 0.050 |
Why?
|
| Tretinoin | 1 | 2004 | 617 | 0.050 |
Why?
|
| Cell Shape | 2 | 2012 | 126 | 0.050 |
Why?
|
| Liver | 1 | 2012 | 3086 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2008 | 817 | 0.050 |
Why?
|
| Algorithms | 1 | 2013 | 3891 | 0.050 |
Why?
|
| Molecular Sequence Data | 5 | 2011 | 6685 | 0.050 |
Why?
|
| Drainage | 1 | 2004 | 462 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 4372 | 0.050 |
Why?
|
| MCF-7 Cells | 2 | 2014 | 547 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 5 | 2012 | 3476 | 0.050 |
Why?
|
| Anxiety | 1 | 2009 | 1240 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2003 | 344 | 0.050 |
Why?
|
| Allelic Imbalance | 1 | 2001 | 41 | 0.050 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2002 | 127 | 0.050 |
Why?
|
| GPI-Linked Proteins | 2 | 2012 | 232 | 0.050 |
Why?
|
| Methylation | 2 | 2013 | 625 | 0.050 |
Why?
|
| Cells, Cultured | 4 | 2012 | 5694 | 0.050 |
Why?
|
| RNA, Small Interfering | 3 | 2012 | 2196 | 0.050 |
Why?
|
| MicroRNAs | 2 | 2012 | 2887 | 0.050 |
Why?
|
| Organ Specificity | 2 | 2012 | 737 | 0.050 |
Why?
|
| Mice, Inbred CBA | 2 | 1991 | 79 | 0.050 |
Why?
|
| Pancreatitis | 1 | 2003 | 295 | 0.050 |
Why?
|
| Karyotyping | 1 | 2002 | 1063 | 0.050 |
Why?
|
| Stomach | 1 | 2003 | 402 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 1269 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2003 | 512 | 0.050 |
Why?
|
| Mediastinum | 1 | 2002 | 276 | 0.040 |
Why?
|
| Exercise | 1 | 2008 | 1184 | 0.040 |
Why?
|
| Proteasome Inhibitors | 2 | 2012 | 235 | 0.040 |
Why?
|
| Heterozygote | 3 | 1993 | 1056 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2001 | 277 | 0.040 |
Why?
|
| Phosphothreonine | 1 | 1999 | 23 | 0.040 |
Why?
|
| Structure-Activity Relationship | 2 | 2014 | 979 | 0.040 |
Why?
|
| Lung Neoplasms | 5 | 2010 | 12033 | 0.040 |
Why?
|
| Critical Care | 1 | 2005 | 796 | 0.040 |
Why?
|
| Protein Binding | 3 | 2013 | 3485 | 0.040 |
Why?
|
| Calcinosis | 2 | 2012 | 426 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2000 | 497 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 1998 | 453 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 2 | 1999 | 809 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2001 | 494 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2012 | 593 | 0.040 |
Why?
|
| Macrophages | 1 | 2005 | 1350 | 0.040 |
Why?
|
| Cell Division | 4 | 2004 | 2657 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2003 | 823 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 3 | 2013 | 2400 | 0.040 |
Why?
|
| Genetic Markers | 2 | 1998 | 1075 | 0.040 |
Why?
|
| Caregivers | 1 | 2004 | 752 | 0.040 |
Why?
|
| England | 1 | 2007 | 73 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 2 | 1998 | 1903 | 0.040 |
Why?
|
| Hernia, Inguinal | 1 | 1997 | 51 | 0.040 |
Why?
|
| RNA Interference | 2 | 2012 | 1388 | 0.040 |
Why?
|
| Length of Stay | 1 | 2004 | 2007 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2007 | 75 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2001 | 1474 | 0.030 |
Why?
|
| Esophageal Perforation | 1 | 1996 | 28 | 0.030 |
Why?
|
| DNA | 4 | 1993 | 3050 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2012 | 1570 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 5257 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 4795 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 1999 | 1111 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 1996 | 195 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2001 | 1347 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 1995 | 107 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 4958 | 0.030 |
Why?
|
| Shoulder Joint | 1 | 1995 | 63 | 0.030 |
Why?
|
| DNA Damage | 3 | 2010 | 1989 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 2471 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2014 | 88 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 3216 | 0.030 |
Why?
|
| Aging | 2 | 2013 | 1534 | 0.030 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 2013 | 30 | 0.030 |
Why?
|
| Biomarkers | 3 | 2008 | 5051 | 0.030 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2014 | 119 | 0.030 |
Why?
|
| Protein Stability | 1 | 2014 | 377 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 4961 | 0.030 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2012 | 43 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2014 | 248 | 0.030 |
Why?
|
| Child | 2 | 2011 | 30559 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2012 | 40 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2013 | 139 | 0.030 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2012 | 32 | 0.030 |
Why?
|
| Photochemical Processes | 1 | 2012 | 9 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2011 | 2828 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2012 | 120 | 0.030 |
Why?
|
| Polydioxanone | 1 | 1992 | 7 | 0.030 |
Why?
|
| Transcription Factor HES-1 | 1 | 2012 | 47 | 0.030 |
Why?
|
| British Columbia | 1 | 2012 | 26 | 0.030 |
Why?
|
| Rodentia | 1 | 2012 | 71 | 0.030 |
Why?
|
| Polypropylenes | 1 | 1992 | 25 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2013 | 236 | 0.030 |
Why?
|
| Nevus | 1 | 2013 | 116 | 0.030 |
Why?
|
| Exons | 2 | 1993 | 1383 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2012 | 167 | 0.020 |
Why?
|
| Sample Size | 1 | 2012 | 213 | 0.020 |
Why?
|
| Mastitis | 1 | 1991 | 12 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 267 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2012 | 1690 | 0.020 |
Why?
|
| Fiber Optic Technology | 1 | 1992 | 146 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 284 | 0.020 |
Why?
|
| Conscious Sedation | 1 | 1992 | 102 | 0.020 |
Why?
|
| Cell Size | 1 | 2012 | 140 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2012 | 318 | 0.020 |
Why?
|
| Europe | 1 | 2013 | 658 | 0.020 |
Why?
|
| Basement Membrane | 1 | 2012 | 143 | 0.020 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2011 | 62 | 0.020 |
Why?
|
| Sutures | 1 | 1992 | 93 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2009 | 5923 | 0.020 |
Why?
|
| Anesthesia, Local | 1 | 1991 | 64 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2012 | 268 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2012 | 318 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 290 | 0.020 |
Why?
|
| Reference Values | 1 | 1993 | 1133 | 0.020 |
Why?
|
| BRCA2 Protein | 1 | 2013 | 380 | 0.020 |
Why?
|
| Aneugens | 1 | 2010 | 1 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2014 | 1254 | 0.020 |
Why?
|
| Endoglin | 1 | 2010 | 42 | 0.020 |
Why?
|
| Genes, Suppressor | 1 | 1990 | 24 | 0.020 |
Why?
|
| Curriculum | 1 | 1997 | 919 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2010 | 64 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2011 | 183 | 0.020 |
Why?
|
| Prostatic Neoplasms | 2 | 2004 | 5866 | 0.020 |
Why?
|
| International Agencies | 1 | 2010 | 108 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 418 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 1997 | 901 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 334 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2012 | 4130 | 0.020 |
Why?
|
| Immunoblotting | 2 | 2005 | 895 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2010 | 193 | 0.020 |
Why?
|
| France | 1 | 2010 | 122 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2011 | 218 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2010 | 189 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 595 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 749 | 0.020 |
Why?
|
| BRCA1 Protein | 1 | 2013 | 528 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2012 | 579 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2010 | 354 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2010 | 269 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 2011 | 141 | 0.020 |
Why?
|
| Zebrafish | 1 | 2012 | 457 | 0.020 |
Why?
|
| Hypoxia | 1 | 1992 | 472 | 0.020 |
Why?
|
| Cadherins | 1 | 2012 | 657 | 0.020 |
Why?
|
| Chromosomes | 1 | 1990 | 325 | 0.020 |
Why?
|
| Heart Rate | 1 | 1992 | 742 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2010 | 271 | 0.020 |
Why?
|
| DNA Primers | 1 | 2011 | 1496 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2010 | 4567 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1267 | 0.020 |
Why?
|
| Dogs | 1 | 2011 | 1160 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2010 | 382 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1990 | 471 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 2 | 2005 | 1472 | 0.020 |
Why?
|
| Histone Acetyltransferases | 1 | 2011 | 433 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2012 | 1028 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 964 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2009 | 230 | 0.020 |
Why?
|
| Pain | 1 | 1997 | 1694 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1199 | 0.020 |
Why?
|
| Propensity Score | 1 | 2012 | 772 | 0.020 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2008 | 32 | 0.020 |
Why?
|
| Colonoscopy | 1 | 1992 | 522 | 0.020 |
Why?
|
| Sirtuin 2 | 1 | 2008 | 18 | 0.020 |
Why?
|
| Mitotic Index | 1 | 2008 | 162 | 0.020 |
Why?
|
| Tubulin | 1 | 2008 | 202 | 0.020 |
Why?
|
| Sirtuins | 1 | 2008 | 43 | 0.020 |
Why?
|
| Tenascin | 1 | 2008 | 51 | 0.020 |
Why?
|
| Cyclin E | 1 | 2010 | 283 | 0.020 |
Why?
|
| Cell Line | 2 | 2010 | 5338 | 0.020 |
Why?
|
| Sirtuin 1 | 1 | 2008 | 77 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2012 | 799 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 2315 | 0.020 |
Why?
|
| Wound Healing | 1 | 1992 | 749 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 676 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2007 | 95 | 0.020 |
Why?
|
| Epitopes | 2 | 1999 | 707 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 1017 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 1933 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1992 | 1154 | 0.020 |
Why?
|
| Blood Pressure | 1 | 1992 | 1568 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2006 | 251 | 0.020 |
Why?
|
| Mammals | 1 | 2008 | 369 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2006 | 242 | 0.020 |
Why?
|
| Mitosis | 1 | 2008 | 681 | 0.020 |
Why?
|
| Patient Selection | 1 | 2013 | 2025 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 361 | 0.020 |
Why?
|
| Autophagy | 1 | 2012 | 911 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 1992 | 2357 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 3063 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2006 | 655 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2013 | 2166 | 0.020 |
Why?
|
| Emotions | 1 | 2009 | 560 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 1430 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 2057 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 1581 | 0.020 |
Why?
|
| Dyspepsia | 1 | 2006 | 113 | 0.020 |
Why?
|
| Phospholipase C delta | 1 | 2004 | 3 | 0.020 |
Why?
|
| U937 Cells | 1 | 2005 | 178 | 0.020 |
Why?
|
| Ethylenediamines | 1 | 2004 | 22 | 0.010 |
Why?
|
| Splenectomy | 1 | 2005 | 168 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2012 | 1718 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 2004 | 62 | 0.010 |
Why?
|
| Prevalence | 1 | 1992 | 3404 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2008 | 662 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 2422 | 0.010 |
Why?
|
| Carbazoles | 1 | 2004 | 88 | 0.010 |
Why?
|
| Peptides | 1 | 2010 | 1504 | 0.010 |
Why?
|
| Haloperidol | 1 | 2004 | 70 | 0.010 |
Why?
|
| Cell Movement | 1 | 2011 | 2472 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 589 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2004 | 232 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2013 | 2457 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2005 | 927 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 453 | 0.010 |
Why?
|
| Hypertension | 1 | 2012 | 1591 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2004 | 541 | 0.010 |
Why?
|
| Cattle | 1 | 2004 | 833 | 0.010 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 2178 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2004 | 282 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 5056 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2004 | 648 | 0.010 |
Why?
|
| Occupational Health | 1 | 1992 | 90 | 0.010 |
Why?
|
| Caspases | 1 | 2004 | 679 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1992 | 191 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 1992 | 121 | 0.010 |
Why?
|
| Rats | 1 | 1990 | 6441 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 518 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 2399 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 1341 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 2353 | 0.010 |
Why?
|
| Oligonucleotide Probes | 2 | 1990 | 154 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 4492 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2004 | 562 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2008 | 2123 | 0.010 |
Why?
|
| Brain | 1 | 1993 | 4208 | 0.010 |
Why?
|
| Isoelectric Point | 1 | 1999 | 35 | 0.010 |
Why?
|
| Spodoptera | 1 | 1999 | 81 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 909 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 1696 | 0.010 |
Why?
|
| Lung | 1 | 2010 | 3298 | 0.010 |
Why?
|
| Heart Failure | 1 | 2012 | 2330 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2005 | 1149 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1999 | 336 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2005 | 1015 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1998 | 350 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 4019 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1999 | 264 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1998 | 603 | 0.010 |
Why?
|
| Pedigree | 2 | 1992 | 2042 | 0.010 |
Why?
|
| Data Collection | 1 | 1999 | 608 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1994 | 223 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2005 | 4116 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1999 | 1309 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 3028 | 0.010 |
Why?
|
| Causality | 1 | 1992 | 176 | 0.010 |
Why?
|
| Contusions | 1 | 1991 | 21 | 0.010 |
Why?
|
| Wound Infection | 1 | 1991 | 66 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 1998 | 1716 | 0.010 |
Why?
|
| Autoradiography | 1 | 1990 | 154 | 0.010 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1990 | 92 | 0.010 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1990 | 56 | 0.010 |
Why?
|
| Hematoma | 1 | 1991 | 156 | 0.010 |
Why?
|
| Codon | 1 | 1990 | 261 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1991 | 603 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1994 | 1557 | 0.000 |
Why?
|
| Adenoma | 1 | 1990 | 740 | 0.000 |
Why?
|
| Intestinal Mucosa | 1 | 1990 | 1105 | 0.000 |
Why?
|